The Clinical phase will start in Q1 2025. CimCure’s partner, the Dutch vaccine contract development and manufacturing organisation (CDMO) Intravacc, is currently producing the lead compound.

The company will continue to work on next-generation vaccines that give better results or perform better in certain indications. In addition, CimCure will develop multi-targeted vaccines, directed towards several targets in the vasculature, the tumour stroma and/or the tumour cells themselves.

CimCure’s end goal is to create three to five vaccines able to cover the treatment of all forms of solid cancer. CimCure expects its first vaccine to be on the market by 2028.

Our investors

CimCure is privately held and backed by world-class investors. We have also received non-dilutive funding from national and European grants.
We are backed by the following investors: Positron, Medex15, Reunion Capital Private investors.

To discuss investment opportunities please contact us:

Our partners

CimCure works with strong partners in the development of vaccins. Amsterdam University Medical Centers: Amsterdam UMC, Intravac